Your browser is no longer supported. Please, upgrade your browser.
Constellation Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.03 Insider Own1.53% Shs Outstand47.84M Perf Week0.00%
Market Cap1.61B Forward P/E- EPS next Y-3.95 Insider Trans-7.45% Shs Float47.18M Perf Month75.52%
Income-141.00M PEG- EPS next Q-0.88 Inst Own- Short Float16.12% Perf Quarter9.95%
Sales- P/S- EPS this Y-37.30% Inst Trans2.40% Short Ratio5.93 Perf Half Y15.13%
Book/sh7.89 P/B4.27 EPS next Y-10.60% ROA-29.90% Target Price41.88 Perf Year-2.32%
Cash/sh8.00 P/C4.21 EPS next 5Y- ROE-33.10% 52W Range17.00 - 40.84 Perf YTD17.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.38% Beta-
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low98.47% ATR1.15
Employees154 Current Ratio15.40 Sales Q/Q- Oper. Margin- RSI (14)82.75 Volatility0.46% 2.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-37.50% Profit Margin- Rel Volume0.65 Prev Close33.70
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume1.28M Price33.74
Recom2.70 SMA2028.62% SMA5043.36% SMA20030.67% Volume625,275 Change0.12%
Jun-04-21Downgrade Jefferies Buy → Hold $33 → $34
Jun-03-21Downgrade Cowen Outperform → Market Perform
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $50
Sep-08-20Downgrade Oppenheimer Outperform → Perform
Jul-20-20Resumed Jefferies Buy
Jun-24-20Initiated JMP Securities Mkt Perform $36
May-07-20Reiterated H.C. Wainwright Buy $50 → $75
Feb-13-20Initiated SunTrust Buy $50
Feb-07-20Initiated Cowen Outperform
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $43 → $42
Sep-04-19Initiated RBC Capital Mkts Outperform $20
Jan-29-19Initiated Robert W. Baird Outperform $17
Dec-20-18Initiated H.C. Wainwright Buy $18
Dec-20-18Initiated H.C. Wainwright Buy
Aug-13-18Initiated JP Morgan Overweight $17
Jun-15-21 09:30AM  
Jun-11-21 08:15PM  
Jun-10-21 11:25PM  
Jun-09-21 01:04PM  
Jun-08-21 03:09PM  
Jun-07-21 06:02PM  
Jun-05-21 06:12PM  
Jun-04-21 11:47PM  
Jun-03-21 07:07PM  
Jun-02-21 06:03PM  
May-31-21 09:00AM  
May-10-21 05:30PM  
Apr-27-21 11:30AM  
Apr-08-21 11:10AM  
Feb-26-21 12:40AM  
Feb-24-21 10:30PM  
Feb-19-21 04:00PM  
Feb-18-21 10:00AM  
Feb-16-21 01:27PM  
Jan-25-21 12:32PM  
Jan-07-21 09:30AM  
Jan-06-21 10:00AM  
Dec-07-20 04:20PM  
Dec-06-20 08:00AM  
Nov-23-20 01:00PM  
Nov-10-20 10:22AM  
Oct-29-20 07:00AM  
Oct-19-20 02:00PM  
Sep-10-20 10:06AM  
Sep-09-20 03:00PM  
Sep-03-20 10:21AM  
Aug-05-20 07:00AM  
Aug-04-20 11:08AM  
Jul-31-20 12:00PM  
Jul-20-20 12:15PM  
Jul-15-20 01:15PM  
Jul-06-20 12:13PM  
Jun-22-20 04:35PM  
Jun-16-20 08:27PM  
Jun-15-20 04:01PM  
Jun-12-20 02:30AM  
Jun-10-20 11:30AM  
Jun-08-20 08:00AM  
May-29-20 09:00AM  
May-28-20 12:00PM  
May-25-20 12:00PM  
May-14-20 09:24AM  
May-09-20 08:22PM  
May-06-20 03:32PM  
May-05-20 02:06PM  
Apr-28-20 09:00AM  
Apr-24-20 12:00PM  
Apr-06-20 07:00AM  
Mar-24-20 08:58AM  
Mar-16-20 12:00PM  
Mar-10-20 04:12PM  
Mar-06-20 01:00PM  
Feb-26-20 09:00AM  
Feb-19-20 10:35AM  
Jan-09-20 02:50PM  
Jan-06-20 12:34PM  
Dec-27-19 02:19PM  
Dec-16-19 06:00AM  
Dec-13-19 04:05PM  
Dec-10-19 09:05PM  
Dec-09-19 04:18PM  
Dec-02-19 11:00AM  
Nov-29-19 12:15PM  
Nov-25-19 12:43PM  
Nov-13-19 09:00AM  
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSMITH MARK ADirectorMar 04Option Exercise0.0014,987014,987Mar 08 05:44 PM
Reeve EmmaChief Financial OfficerFeb 22Option Exercise8.046,26050,3306,260Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 22Sale37.606,260235,3730Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 19Option Exercise8.044,01032,2404,010Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 19Sale37.714,010151,2180Feb 23 05:58 PM
Reeve EmmaChief Financial OfficerFeb 18Option Exercise8.041,1008,8441,100Feb 19 04:17 PM
Reeve EmmaChief Financial OfficerFeb 18Sale37.581,10041,3430Feb 19 04:17 PM
Reeve EmmaChief Financial OfficerFeb 17Option Exercise8.044103,296410Feb 19 04:17 PM
COLUMN GROUP L P10% OwnerFeb 17Sale36.9510,000369,50399,155Feb 19 05:31 PM
COLUMN GROUP L P10% OwnerFeb 17Sale36.9510,000369,50399,155Feb 19 05:32 PM
Reeve EmmaChief Financial OfficerFeb 17Sale37.5641015,3980Feb 19 04:17 PM
Valentine KarenSee RemarksJan 19Option Exercise11.5017,203197,83417,203Jan 20 05:56 PM
Valentine KarenSee RemarksJan 19Sale33.9717,203584,4630Jan 20 05:56 PM
Reeve EmmaChief Financial OfficerDec 21Option Exercise6.815,72038,9755,720Dec 22 04:53 PM
Reeve EmmaChief Financial OfficerDec 21Sale35.115,720200,8050Dec 22 04:53 PM
GOLDSMITH MARK ADirectorDec 21Sale35.024,020140,769139,043Dec 28 04:02 PM